patients with advanced stage follicular lymphoma who received rituximab in combination with chemotherapy were significantly less likely to experience treatment failure than patients who received ...

—Risk stratification in follicular lymphoma relies on clinical parameters, lab tests, and histology to determine which patients should receive early treatment. Genetic tests may soon be added to ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

For evaluating response to treatment for follicular lymphoma, computed tomography (CT) has been considered the gold standard, and most clinical studies and trials have used CT as a tool for ...

NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the drug up to four years to prove its value to patients. The agreement has been hailed as a ...

Treatment with the CAR-T cell therapy Yescarta (axicabtagene ciloleucel) continued to demonstrate durable responses after a median follow-up of more than five years in patients with ...